Company news
Cogent Biosciences, Inc. (NASDAQ:COGT) news
Cogent Biosciences, Inc. news releases on 6ix. Latest, Sep 15, 2026: Cogent Biosciences Announces FDA Acceptance of New Drug Application (NDA)…
Press releases & updates
Cogent Biosciences Announces FDA Acceptance of New Drug Application (NDA) for Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM)
September 15, 2026
Cogent Biosciences Reports Recent Business Highlights and Second Quarter 2026 Financial Results
August 10, 2026
Cogent Biosciences Announces Submission of New Drug Application (NDA) for Bezuclastinib in Advanced Systemic Mastocytosis (AdvSM)
June 30, 2026
Cogent Biosciences Announces Preclinical Data from Novel JAK2 V617F Inhibitor at the 2026 European Hematology Association (EHA) Congress
June 12, 2026
Cogent Biosciences Announces Detailed Data from APEX Pivotal Trial of Bezuclastinib in Patients with Advanced Systemic Mastocytosis at the 2026 European Hematology Association (EHA) Congress
June 12, 2026
Cogent Biosciences Announces Detailed Clinical Data from PEAK Phase 3 Trial with Bezuclastinib in Combination with Sunitinib in Gastrointestinal Stromal Tumors (GIST) at 2026 American Society of Clinical Oncology (ASCO) Annual Meeting
May 29, 2026
Cogent Biosciences Announces FDA Acceptance of New Drug Application (NDA) with Priority Review for Bezuclastinib in Combination with Sunitinib for Patients with GIST
May 28, 2026
Cogent Biosciences Announces Participation in the 2026 Jefferies Global Healthcare Conference
May 26, 2026
Cogent Biosciences Announces Multiple Presentations at the European Hematology Association (EHA) 2026 Congress
May 12, 2026
Cogent Biosciences Reports Recent Business Highlights and First Quarter 2026 Financial Results
May 5, 2026
Cogent Biosciences Announces Oral Presentation of Positive Phase 3 PEAK Trial in Gastrointestinal Stromal Tumors (GIST) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting
April 20, 2026
Cogent Biosciences Announces Poster Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2026
April 17, 2026
Cogent Biosciences Announces FDA Acceptance of New Drug Application for Bezuclastinib in Patients with NonAdvanced Systemic Mastocytosis (NonAdvSM)
March 15, 2026
Cogent Biosciences Highlights Additional Data with Six Bezuclastinib Posters from SUMMIT Trial at 2026 AAAAI Annual Meeting
February 27, 2026
Cogent Biosciences Reports Recent Business Highlights and Fourth Quarter and Full Year 2025 Financial Results
February 17, 2026
Cogent Biosciences Announces Multiple SUMMIT Posters at the 2026 AAAAI Annual Meeting
February 10, 2026
Cogent Biosciences Announces Breakthrough Therapy Designation for Bezuclastinib in Combination with Sunitinib for Patients with Gastrointestinal Stromal Tumors (GIST)
January 25, 2026
Cogent Biosciences to Initiate New Drug Application (NDA) Submission for Bezuclastinib Under Real-Time Oncology Review (RTOR)
January 20, 2026
Cogent Biosciences to Initiate New Drug Application (NDA) Submission for Bezuclastinib Under Real-Time Oncology Review (RTOR)
January 19, 2026
Cogent Biosciences Announces Anticipated 2026 Commercial and Clinical Milestones for Bezuclastinib and Precision Therapies Portfolio
January 11, 2026
Cogent Biosciences Announces Presentation at the 44th Annual J.P. Morgan Healthcare Conference
January 5, 2026
Cogent Biosciences Announces Submission of New Drug Application for Bezuclastinib in NonAdvanced Systemic Mastocytosis
December 29, 2025
Cogent Biosciences Announces Positive Top-line Results of APEX Trial of Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM)
December 7, 2025
Cogent Biosciences Presents Full SUMMIT Results of Bezuclastinib in Patients with NonAdvanced Systemic Mastocytosis (NonAdvSM) at the 67th Annual Meeting of the American Society of Hematology (ASH)
December 5, 2025
Cogent Biosciences Announces Pricing of Concurrent Public Offerings of Common Stock and 1.625% Convertible Senior Notes Due 2031
November 10, 2025
Cogent Biosciences Reports Positive Results from Bezuclastinib PEAK Phase 3 Trial in Gastrointestinal Stromal Tumors (GIST)
November 9, 2025
Cogent Biosciences Announces Proposed Concurrent Public Offerings of Convertible Senior Notes Due 2031 and Common Stock
November 9, 2025
Cogent Biosciences Reports Recent Business Highlights and Third Quarter 2025 Financial Results
November 3, 2025
Cogent Biosciences Reports Recent Business Highlights and Third Quarter 2025 Financial Results
November 2, 2025
Cogent Biosciences Announces Multiple Presentations at the 67th Annual American Society of Hematology (ASH) Meeting
November 2, 2025
Cogent Biosciences Announces KRAS Poster Presentation at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
October 23, 2025
Cogent Biosciences Announces FDA Breakthrough Therapy Designation for Bezuclastinib
October 19, 2025
Cogent Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 28, 2025
Cogent Biosciences Announces Participation in the Citi Biopharma Conference
August 25, 2025
Cogent Biosciences Reports Recent Business Highlights and Second Quarter 2025 Financial Results
August 4, 2025
Cogent Biosciences Announces Closing of Upsized Public Offering of Shares of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
July 9, 2025
Cogent Biosciences Announces Proposed $150 Million Public Offering of Common Stock
July 7, 2025
Cogent Biosciences Announces Pricing of Upsized Public Offering of Shares of Common Stock
July 7, 2025
Cogent Biosciences Announces Positive Top-line Results Achieving Statistical Significance Across All Primary and Key Secondary Endpoints from the SUMMIT Trial of Bezuclastinib in Patients with Non-Advanced Systemic Mastocytosis
July 6, 2025
Cogent Biosciences Secures up to $400 Million in Non-Dilutive Financing
June 10, 2025
Cogent Biosciences Announces Participation in the Jefferies Global Healthcare Conference
May 28, 2025
Cogent Biosciences Reports First Quarter 2025 Financial Results
May 5, 2025
Cogent Biosciences Presents Four Posters at the American Association for Cancer Research Annual Meeting 2025 and Announces Two New Leaders
April 24, 2025
Cogent Biosciences Announces Multiple Poster Presentations at 2025 American Association for Cancer Research (AACR) Annual Meeting
March 24, 2025
Cogent Biosciences Announces Participation in the Leerink Healthcare Conference
March 6, 2025
Cogent Biosciences Announces SUMMIT Continues to Showcase Powerful Symptomatic Improvement in NonAdvanced Systemic Mastocytosis Patients
February 26, 2025
Cogent Biosciences Reports Recent Business Highlights and Fourth Quarter and Full Year 2024 Financial Results
February 24, 2025
Cogent Biosciences Announces Bezuclastinib Poster in NonAdvanced Systemic Mastocytosis (NonAdvSM) at the 2025 AAAAI Annual Meeting
February 9, 2025
Cogent Biosciences to Participate in the Guggenheim Biotech Conference
January 29, 2025
Cogent Biosciences Announces Planned 2025 Milestones for Bezuclastinib and Emerging Portfolio of Selective and Potent Targeted Therapeutics
January 12, 2025